Aug 27, 2023, 15:01
Andrius Žučenka: Excited that our center is currently enrolling R/R AML pts in 2 clinical trials.
Andrius Žučenka, hematologist, researcher, lecturer and PhD candidate at Vilnius University Hospital Santaros Klinikos, made the following post on Twitter:
“Excited that our center is currently enrolling R/R AML pts in 2 clinical trials:
-Revumenib (Menin inhibitor) for KMT2Ar or NPM1m (+ALL,MPAL). AUGMENT-101, Phase 2
-MP0533 (AntiCD33+CD123+CD70 T-cell-engager DARPin), mutation agnostic. MP0533-CP101, Phase 1”
Source: Andrius Žučenka / Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 02:34
Nov 19, 2024, 02:18
Nov 18, 2024, 22:22
Nov 18, 2024, 22:02
Nov 18, 2024, 21:55
Nov 18, 2024, 20:54